TY - JOUR
T1 - Long-Term physical stability, sterility, and anti-vegf bioactivity of repackaged bevacizumab in 2-ml glass vials
AU - Peterson, Jan S.
AU - Rockwell, Kenneth
AU - Scott, Ingrid U.
AU - Ip, Michael S.
AU - Vanveldhuisen, Paul C.
AU - Blodi, Barbara A.
N1 - Funding Information:
Research reported in this publication was supported by the National Eye Institute of the National Institutes of Health under Award Number U10EY023529.
Publisher Copyright:
Copyright © by Ophthalmic Communications Society, Inc.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Purpose:Repackaged bevacizumab in single-dose, prefilled syringes for intravitreal injection is available, but with shelf life limited from 60 days to 90 days. For the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2), 2-mL sterile glass vials were used rather than prefilled syringes to provide a longer shelf life for study supplies.Methods:Repackaged bevacizumab in glass vials was tested at release and, for 1 lot, after 1, 3, 6, and 12 months for physical stability, including concentration, purity and appearance, and for sterility and endotoxins. Vials from 2 lots were tested at release and after 20 months and 21 months, respectively. One lot was tested at 21 months for anti-VEGF bioactivity compared with a fresh supply of commercial bevacizumab.Results:Repackaged bevacizumab in 2-mL glass vials continued to meet all quality release specifications and remain sterile for up to 21 months. In addition, no degradation in anti-VEGF bioactivity was observed at 21 months compared with a fresh bevacizumab control.Conclusion:Bevacizumab can be repackaged into small, single-dose glass vials for intravitreal injection and the qualities of the commercial product maintained, including anti-VEGF bioactivity, for up to 21 months in refrigerated storage. Consideration should be given to repackaging bevacizumab for ophthalmic use in small glass vials as opposed to plastic syringes.
AB - Purpose:Repackaged bevacizumab in single-dose, prefilled syringes for intravitreal injection is available, but with shelf life limited from 60 days to 90 days. For the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2), 2-mL sterile glass vials were used rather than prefilled syringes to provide a longer shelf life for study supplies.Methods:Repackaged bevacizumab in glass vials was tested at release and, for 1 lot, after 1, 3, 6, and 12 months for physical stability, including concentration, purity and appearance, and for sterility and endotoxins. Vials from 2 lots were tested at release and after 20 months and 21 months, respectively. One lot was tested at 21 months for anti-VEGF bioactivity compared with a fresh supply of commercial bevacizumab.Results:Repackaged bevacizumab in 2-mL glass vials continued to meet all quality release specifications and remain sterile for up to 21 months. In addition, no degradation in anti-VEGF bioactivity was observed at 21 months compared with a fresh bevacizumab control.Conclusion:Bevacizumab can be repackaged into small, single-dose glass vials for intravitreal injection and the qualities of the commercial product maintained, including anti-VEGF bioactivity, for up to 21 months in refrigerated storage. Consideration should be given to repackaging bevacizumab for ophthalmic use in small glass vials as opposed to plastic syringes.
UR - http://www.scopus.com/inward/record.url?scp=85069692844&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069692844&partnerID=8YFLogxK
U2 - 10.1097/IAE.0000000000002212
DO - 10.1097/IAE.0000000000002212
M3 - Article
C2 - 29746405
AN - SCOPUS:85069692844
SN - 0275-004X
VL - 39
SP - 1802
EP - 1809
JO - Retina
JF - Retina
IS - 9
ER -